Enveric Biosciences (ENVB) EPS (Basic) Growth (1y) (2011 - 2026)
Enveric Biosciences (ENVB) EPS (Basic) Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | -16.29% |
| 10 | Enveric Biosciences | 5.72 Mn | -2.57 Mn | - | 93.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.58% |
| Dec 31, 2025 | 83.97% |
| Sep 30, 2025 | 74.91% |
| Jun 30, 2025 | 73.88% |
| Mar 31, 2025 | 86.80% |
| Dec 31, 2024 | 73.72% |
| Sep 30, 2024 | 81.63% |
| Jun 30, 2024 | 91.84% |
| Mar 31, 2024 | 73.42% |
| Dec 31, 2023 | 73.86% |
| Sep 30, 2023 | 10.47% |
| Jun 30, 2023 | -11.40% |
| Mar 31, 2023 | 56.75% |
| Dec 31, 2022 | 93.17% |
| Sep 30, 2022 | 75.16% |
| Jun 30, 2022 | -28.03% |
| Mar 31, 2022 | 76.59% |
| Dec 31, 2021 | -300.99% |
| Sep 30, 2021 | 85.51% |
| Jun 30, 2021 | 97.77% |